The quest for what’s next in oncology
For us, next-generation drug discovery in oncology takes courage and persistence, the courage to embrace and invest in areas of uncertainty and the persistence to seek out and pursue innovative science.
This unique approach to research has resulted in a robust and diverse pipeline that isn’t limited to one cancer type or mechanism. All of our compounds push the boundaries of biology—aiming to propel cancer treatment forward.
Mechanisms we are currently exploring include:ROS
Discovery and the promise of purposeful science
David J Bearss, Ph.D., Chief Scientific Officer and Global Head of Research
Excellence in global collaboration
As one united team, we work together across geographies. Collectively, we bring together distinct proficiencies and strengths that are critical to inspiring innovation. In the past decade, our team has advanced and expanded our oncology pipeline to include multiple compounds and even more early discovery programs.
United in mission and mindset
Our team is relentless in their pursuit of life-changing discoveries. Through purposeful science, we aim to uncover the most impactful treatments of tomorrow.
“I think we have the opportunity to make a real difference in the lives of patients. We have all the expertise to excel and significantly contribute to the advancement of oncology research.”
—Steve Warner, Ph.D., Vice President, Head of Discovery
“Our new integrated organization means that a range of talents are combined in important ways that can result in bringing highly innovative treatments to the market faster than ever.”
—Setsuko Yamamoto, Ph.D., Senior Director, DSP Cancer Institute
“Our Discovery team has a unique opportunity to use our passion to advance science that takes us to new, highly meaningful areas of research where we can help patients.”
—Hitoshi Ban, Ph.D., Senior Principal Scientist, DSP Cancer Institute